ArticleArtificial organs2026
Differential Impact of Polymyxin B Hemadsorption on Long-Term Mortality in Septic Shock: A Retrospective Analysis of Intra-Abdominal Versus Extra-Abdominal Infections.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic success and clinical neutrality: lessons from the OXICARD trial.Journal of thoracic disease · 2026Article
- Immature Granulocyte Trajectories Following Hemadsorption as Indicators of Immune Dysregulation and Mortality.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe long-term benefit of polymyxin B hemadsorption (PMX-HA) in septic shock patients remains unclear and may depend on the site of infection. We evaluated the association between PMX-HA use and 1-year mortality in patients with intra-abdominal infection (IAI) and extra-abdominal infection (EAI).
methodsWe retrospectively analyzed adult patients with septic shock (Sepsis-3) admitted to an ICU between January 2017 and July 2023. Patients were categorized as IAI or EAI and further stratified by PMX-HA use. One-year mortality was assessed using Kaplan-Meier analysis, multivariable Cox regression (adjusted for age, sex, and SOFA score), and inverse probability of treatment weighting (IPTW), balancing age, sex, SOFA, CRRT use, and with or without surgical and/or radiological interventions.
resultsAmong 182 patients (98 IAI, 84 EAI), PMX-HA was administered to 71 IAI and 32 EAI patients. In the IAI group, PMX-HA was associated with significantly lower 1-year mortality (32.3% vs. 59.2%, p = 0.005), supported by Cox regression (adjusted HR: 0.485; 95% CI: 0.252-0.935; p = 0.031) and IPTW (weighted HR: 0.415; 95% CI: 0.215-0.787; p = 0.007). In contrast, in the EAI group, 1-year mortality was similar between the non-PMX and PMX groups (44.4% vs. 56.6%, p = 0.516), with no significant association in Cox analysis (adjusted HR: 0.790; 95% CI: 0.404-1.543; p = 0.49) or IPTW (weighted HR: 0.85; 95% CI: 0.446-1.617; p = 0.62).
conclusionPMX-HA was significantly associated with a lower risk of 1-year mortality in patients with IAI, but not in those with EAI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.